Blanca Estela Del Rio-Navarro

Prof. Blanca Estela Del Rio-Navarro

Head of Allergy and Immunology Service at the Hospital Infantil de México Federico Gómez
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2006 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
FEFrancisco J Espinosa-Rosales
Francisco J Espinosa-Rosales
VFVicki Flenady
Vicki Flenady
JSJuan Jl Sienra-Monge
Juan Jl Sienra-Monge

2 August 2014 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
SBSupinda Bunyavanich
Supinda Bunyavanich
ESEric E. Schadt
Eric E. Schadt
BHBlanca E Himes
Blanca E Himes
Jessica Lasky-SuJessica Lasky-Su
Jessica Lasky-Su
WQWeiliang Qiu
Weiliang Qiu
SWScott T. Weiss
Scott T. Weiss
Allergic rhinitis is a common disease whose genetic basis is incompletely explained. We report an integrated genomic analysis of allergic rhinitis. We performed genome wide association studies (GWAS) of allergic rhinitis in 5633 ethnically diverse North American subjects. Next, we profiled gene expression in disease-relevant tissue (peripheral blood CD4+ lymphocytes) collected from subjects who had been genotyped. We then integrated the GWAS and gene expression data using expression single nucleotide (eSNP), coexpression network, and pathway approaches to identify the biologic relevance of our GWAS. GWAS revealed ethnicity-specific findings, with 4 genome-wide significant loci among Latinos and 1 genome-wide significant locus in the GWAS meta-analysis across ethnic groups. To identify biologic context for these results, we constructed a coexpression network to define modules of genes with similar patterns of CD4+ gene expression (coexpression modules) that could serve as constructs of broader gene expression. 6 of the 22 GWAS loci with P-value ≤ 1x10−6 tagged one particular coexpression module (4.0-fold enrichment, P-value 0.0029), and this module also had the greatest enrichment (3.4-fold enrichment, P-value 2.6 × 10−24) for allergic rhinitis-associated eSNPs (genetic variants associated with both gene expression and allergic rhinitis). The integrated GWAS, coexpression network, and eSNP results therefore supported this coexpression module as an allergic rhinitis module. Pathway analysis revealed that the module was enriched for mitochondrial pathways (8.6-fold enrichment, P-value 4.5 × 10−72). Our results highlight mitochondrial pathways as a target for further investigation of allergic rhinitis mechanism and treatment. Our integrated approach can be applied to provide biologic context for GWAS of other diseases.

1 November 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
PMPaola Viridiana León Mimila
Paola Viridiana León Mimila
HVHugo Villamil-Ramírez
Hugo Villamil-Ramírez
BLBlanca Estela López-Contreras
Blanca Estela López-Contreras
SMSofia Moran-Ramos
Sofia Moran-Ramos
LMLuis Rodrigo Macias
Luis Rodrigo Macias
SCSamuel Canizales-Quinteros
Samuel Canizales-Quinteros
Genome-wide association studies (GWAS) have identified copy number variants (CNVs) associated with obesity in chromosomal regions 1p31.1, 10q11.22, 11q11, 16p12.3, and recently 1p21.1, which contains the salivary amylase gene (AMY1). Recent evidence suggests this enzyme may influence gut microbiota composition through carbohydrate (mainly starch) degradation. The role of these CNVs in obesity has been scarcely explored in the Latino population, and thus the aim of our study was to evaluate the association of 1p31.1, 10q11.22, 11q11, 16p12.3 and 1p21.1 CNVs with obesity in 921 Mexican children, to replicate significant associations in 920 Mexican adults, and to analyze the association of AMY1 copy number with gut microbiota in 75 children and 45 adults. Of the five CNVs analyzed, 1q11 CNV was significantly associated with obesity in children, but not in adults. Only AMY1 CNV was significantly associated with obesity in both age groups. Moreover, gut microbiota analyses revealed a positive correlation between AMY1 copy number and Prevotella abundance. This genus has enzymes and gene clusters essential for complex polysaccharide degradation and utilization. To our knowledge, this is the first study to analyze the association of these five CNVs in the Mexican population and to report a correlation between AMY1 CN and gut microbiota in humans.

1 November 2016 in Journal of Asthma
Verified
Journal Article
Closed access
FHFengyang Huang
Fengyang Huang
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
STSaúl Torres-Alcántara
Saúl Torres-Alcántara
JPJosé Alfredo Pérez-Ontiveros
José Alfredo Pérez-Ontiveros
EREliseo Ruiz-Bedolla
Eliseo Ruiz-Bedolla
EHEnrique Hong
Enrique Hong
Objective: This study was to investigate whether the metabolic abnormalities of adipokines and asymmetrical dimethylarginine (ADMA) associate with pulmonary function deficits in adolescents with obesity and asthma. Methods: This study enrolled 28 obese adolescents with asthma, 46 obese adolescents without asthma, 58 normal-weight adolescents with asthma, and 63 healthy control subjects. Serum levels of leptin, high-molecule-weight (HMW) adiponectin, retinol binding protein 4 (RBP4), asymmetrical dimethylarginine (ADMA), and pulmonary function were qualified. Results: The obese subjects had higher levels of leptin and ADMA but lower levels of HMW adiponectin than the normal-weight subjects with or without asthma. The subjects with asthma had higher levels of RBP4 than those without asthma. The obese adolescents with asthma had lowest forced expiratory lung volume in the first second (FEV1)/forced vital capacity (FVC) ratio among the four study groups. In all the study subjects and in the subjects with asthma alone, the FEV1/FVC ratio associated negatively with leptin, however, such association was rendered non-significant when adjusted for BMI. The pulmonary function deficits associated inversely with BMI percentile in the subjects with asthma. However, the decreased FEV1/FVC ratio was not correlated with HMW adiponectin, RBP4 or ADMA. Conclusions: Our present study confirmed obstructive pattern of pulmonary function characterized by the reduced FEV1/FVC ratio in the obese adolescents with asthma. These pulmonary deficits were associated inversely with the increased BMI percentile.

1 November 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MBMaría Virginia Blandón-Vijil
María Virginia Blandón-Vijil
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
MRMaría Isabel Rojo-Gutiérrez
María Isabel Rojo-Gutiérrez
In the light of the current COVID-19 pandemic, during which the world is confronted with a new, highly contagious virus that suppresses innate immunity as one of its initial virulence mechanisms, thus escaping from the first-line human defense mechanisms, enhancing innate immunity seems a good preventive strategy. Without the intention to write an official systematic review, but more to give an overview of possible strategies, in this review article we discuss several interventions that might stimulate innate immunity and thus our defense against (viral) respiratory tract infections. Some of these interventions can also stimulate the adaptive T- and B-cell responses, but our main focus is on the innate part of immunity. We divide the reviewed interventions in: 1) lifestyle related (exercise, >7 hours sleep, forest walking, meditation/mindfulness, vitamin supplementation); 2) Non-specific immune stimulants (letting fever advance, bacterial vaccines, probiotics, dialyzable leukocyte extract, pidotimod) and 3) specific vaccines with heterologous effect (BCG vaccine, mumps-measles-rubeola vaccine, i.e.). For each of these interventions we briefly comment on their definition, possible mechanisms and evidence of clinical efficacy or lack of it, especially focusing on respiratory tract infections, viral infections and eventually a reduced mortality in severe respiratory infections in the intensive care unit. At the end a summary table demonstrates the best trials supporting (or not) clinical evidence. Several interventions have some degree of evidence for enhancing the innate immune response and thus conveying possible benefit, but specific trials in COVID-19 should be conducted to support solid recommendations.

1 March 2018 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
ENE.M. Navarrete-Rodríguez
E.M. Navarrete-Rodríguez
LRL.A. Ríos-Villalobos
L.A. Ríos-Villalobos
CAC.R. Alcocer-Arreguín
C.R. Alcocer-Arreguín
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
JRJ.M. Del Rio-Chivardi
J.M. Del Rio-Chivardi
RFR.V. Frias
R.V. Frias
Cow's milk protein allergy (CMPA) affects between 0.6 and 0.9% of the general population, and its treatment implies the total elimination of the intake of this protein. Camel's milk has been suggested as an alternative for patients over one year of age who suffer from CMPA due to the difference in the amino acid sequence from that of cow's milk. The objective of this study was to evaluate the safety and tolerability of camel's milk in children with CMPA. Crossed clinical trial for the use of camel's milk vs. amino acid formula, carried out at the Dr. Federico Gómez Children's Hospital of Mexico (HIMFG) on patients between one and 18 years of age with diagnosed CMPA confirmed through double-blind, placebo-controlled food challenges (DBPCFCs). Only those whose allergies were confirmed were randomly placed into two groups: those to be administered camel's milk and those to be administered the amino-acid formula for two weeks, followed by a six-week wash-out period, and then a group crossing for a further two weeks. 49 patients with suspected CMPA were included in the study; the diagnosis was confirmed through DBPCFCs in 15 patients, who were those who participated in the study. After having been administered camel's milk, none of the patients presented adverse effects. Camel's milk is safe and tolerable in patients above one year of age with CMPA and can be considered as a good alternative given the benefit of its taste compared to other formulas.